Gentry Private Wealth LLC trimmed its holdings in shares of Kenvue Inc. (NYSE:KVUE – Free Report) by 3.4% in the third quarter, HoldingsChannel reports. The institutional investor owned 19,211 shares of the company’s stock after selling 686 shares during the quarter. Gentry Private Wealth LLC’s holdings in Kenvue were worth $444,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also modified their holdings of the company. Riverview Trust Co bought a new stake in Kenvue in the third quarter valued at approximately $30,000. Ashton Thomas Securities LLC bought a new stake in Kenvue in the third quarter valued at approximately $35,000. Studio Investment Management LLC increased its stake in Kenvue by 52.1% in the second quarter. Studio Investment Management LLC now owns 2,468 shares of the company’s stock valued at $45,000 after purchasing an additional 845 shares in the last quarter. Deseret Mutual Benefit Administrators increased its stake in Kenvue by 49.7% in the third quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company’s stock valued at $45,000 after purchasing an additional 651 shares in the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new stake in Kenvue in the second quarter valued at approximately $61,000. 97.64% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
KVUE has been the subject of several recent analyst reports. Deutsche Bank Aktiengesellschaft upped their target price on shares of Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. UBS Group upped their price target on shares of Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. JPMorgan Chase & Co. upped their price target on shares of Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Royal Bank of Canada cut shares of Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price target for the company. in a report on Tuesday, September 24th. Finally, Piper Sandler upped their price target on shares of Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a report on Monday, September 23rd. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, Kenvue presently has a consensus rating of “Hold” and a consensus price target of $22.64.
Kenvue Stock Performance
Shares of KVUE opened at $24.08 on Friday. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.31. The firm has a fifty day simple moving average of $22.84 and a 200 day simple moving average of $20.86. The stock has a market capitalization of $46.17 billion, a price-to-earnings ratio of 43.78, a PEG ratio of 2.19 and a beta of 1.36. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.
Kenvue (NYSE:KVUE – Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The firm had revenue of $3.90 billion for the quarter, compared to analyst estimates of $3.92 billion. During the same period in the prior year, the firm posted $0.31 earnings per share. The company’s quarterly revenue was down .4% compared to the same quarter last year. Research analysts forecast that Kenvue Inc. will post 1.07 EPS for the current fiscal year.
Kenvue Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th will be given a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.41%. The ex-dividend date of this dividend is Wednesday, November 13th. Kenvue’s payout ratio is presently 149.09%.
Kenvue Profile
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
See Also
- Five stocks we like better than Kenvue
- Top Stocks Investing in 5G Technology
- Disney’s Magic Strategy: Reinventing the House of Mouse
- What is Put Option Volume?
- Volatility in Semis? 3 Stable Alternatives to NVIDIA and SMCI
- What is MarketRank™? How to Use it
- Vertiv’s Cool Tech Makes Its Stock Red-Hot
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.